AngioDynamics Stock Is Falling Thursday: What's Going On?
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.
Stocks · News reference
AngioDynamics Q1 Adj. EPS $(0.04) Beats $(0.11) Estimate, Sales $80.915M Beat $80.500M Estimate
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. This is a 60 percent increase over losses of $(0.10) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
AngioDynamics shares are trading lower after the company reported Q1 financial results. The company reported a year-over-year decrease in its AngioVac sales.
AngioDynamics Q1 2027 Earnings Call: Complete Transcript
AngioDynamics (NASDAQ:ANGO) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga